In a regulatory filing, Offerpad Solutions disclosed that its director Roberto Sella bought 1M shares of common stock on August 9th in a total transaction size of $1.69M.

In a regulatory filing, T-Mobile disclosed that its Technology President Nevilled Ray sold 50K shares of common stock on August 9th in a total transaction size of $7.26M.

Algonquin Power has approved and declared the following common and preferred share dividends: 18.08c per common share, payable on October 14 to shareholders of record on September 29 for the period from July 1 to September 30; shareholders receiving dividends in cash can elect to receive the dividend in Canadian dollars in the amount of C$0.2312. C$0.32263 per preferred share, Series A, payable in cash on October 3 to preferred share, Series A holders of record on September 15 for the period from June 30 to, but excluding, September 30. C$0.31819 per preferred share, Series D, payable in cash on October 3 to preferred share, Series D holders of record on September 15 for the period from June 30 to, but excluding, September 30. . Plan Shares will be acquired by way of a treasury purchase at the average market price as defined in the Plan less a 3% discount.

Agios Pharmaceuticals announced that data from the core period of the open-label, Phase 2 study of PYRUKYND in adults with non-transfusion-dependent alpha- or beta-thalassemia were published on August 11, 2022, in The Lancet. Data from this study were previously presented at the 2021 European Hematology Association Annual Congress. PYRUKYND is a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase enzymes. "Consistent with previously reported findings, the data reported today underscore the potential of PK activation to improve hallmarks of alpha- and beta-thalassemia, including hemolysis and ineffective erythropoiesis," said Kevin Kuo, M.D., hematologist at University of Toronto, Toronto General Hospital, and an investigator in the study. "Thalassemia is a rare, debilitating lifelong blood disorder characterized by severe complications, with no treatment options for those with alpha-thalassemia and limited options for those with beta-thalassemia. These data demonstrate the potential clinical benefits of mitapivat for a broad spectrum of thalassemia patients and support its continued investigation in pivotal trials."

Taro Pharmaceuticals has initiated a voluntary Type 1 recall to the patient level on six lots of Taro-Zoledronic Acid Injection, 5 mg/100 mL in 100 mL vials. The reason for the recall is that product from these lots may contain particulate matter over the specified requirements. This recall is being conducted with the knowledge of Health Canada. The presence of foreign particulate matter in vials of the affected lots could potentially cause unintended adverse events. Taro has received no reports of serious adverse events associated with this product. Taro-Zoledronic Acid Injection, 5 mg/100 mL is used to increase bone mineral density, to treat and prevent osteoporosis as well as to treat Paget's disease, a condition that causes bone deformities.

In a regulatory filing, Quanterix director Sarah Hlavinka disclosed the purchase of 10.1K common shares of the company on August 11 at a price of $9.89 per share. Shares of Quanterix rose 18.7% today following insider buying activity yesterday evening and are up another 6.2% afterhours.

Hologic (HOLX) announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a 2018 district court ruling that barred Minerva (NERV) from challenging the validity of the patent rights it assigned to Hologic. "We are pleased that the U.S. Court of Appeals has once again ruled in our favor. This important decision confirms that good faith and fair dealing apply to transactions involving patents and provides greater certainty for companies like Hologic who acquire innovative technologies in order to provide physicians and their patients with the latest solutions," said Essex Mitchell, President of Hologic's GYN Surgical Solutions Division. In 2015, Hologic sued Minerva alleging that the company's endometrial ablation system infringes patents acquired by Hologic through its 2004 purchase of Novacept, the developer of the NovaSure endometrial ablation system for abnormal uterine bleeding. The suit alleged that four years after Hologic's acquisition of Novacept, a former Novacept executive founded Minerva and developed and commercialized an endometrial ablation device using the patented technology that was acquired by Hologic in the Novacept transaction. In 2018, a Delaware district court found Minerva liable for patent infringement and barred the company's invalidity defenses under assignor estoppel. A jury awarded Hologic $4.8M in damages for Minerva's infringement. This decision by the U.S. Court of Appeals is the latest decision in Hologic's favor on this matter. In 2019, the Federal Circuit affirmed the district court ruling on infringement and assignor estoppel. In 2021, the U.S. Supreme Court clarified the scope of assignor estoppel and, on remand, the Federal Circuit again ruled in Hologic's favor, holding that Minerva's invalidity challenge contradicted multiple representations made by the Novacept executive, including in assigning the patent. With the Federal Circuit decision, Minerva must now pay Hologic more than $7M in damages, which includes the $4.8M in damages originally awarded plus post-trial damages and interest.

"The landscape of social media is ever-changing, especially among teens who often are on the leading edge of this space. A new Pew Research Center survey of American teenagers ages 13 to 17 finds TikTok has rocketed in popularity since its North American debut several years ago and now is a top social media platform for teens among the platforms covered in this survey. Some 67% of teens say they ever use TikTok, with 16% of all teens saying they use it almost constantly. Meanwhile, the share of teens who say they use Facebook, a dominant social media platform among teens in the Center's 2014-15 survey, has plummeted from 71% then to 32% today. YouTube (GOOG) tops the 2022 teen online landscape among the platforms covered in the Center's new survey, as it is used by 95% of teens. TikTok is next on the list of platforms that were asked about in this survey,67%, followed by Instagram and Snapchat (SNAP), which are both used by about six-in-ten teens. After those platforms come Facebook (META) with 32% and smaller shares who use Twitter (TWTR), Twitch, WhatsApp, Reddit and Tumblr,"wrote Emily Vogels, Risa Gelles-Watnick and Navid Massarat for Pew Research. Reference Link